Drug Price Transparency
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that would require price disclosures on advertisements for prescription drugs. The bill would help ensure that consumers are able to make more…
The Centers for Medicare & Medicaid Services Oct. 21 will host a webinar on meeting its new hospital price transparency requirements becoming effective Jan. 1.
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and…
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs.
AHA writes in support of H.J.Res. 139, a joint resolution for congressional disapproval of a rule relating to "Medicare and Medicaid Programs; Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting."
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February…
CVS Health plans to launch its CVS CostVantage and CVS Caremark TrueCost programs in 2025. CostVantage will define the drug cost and related reimbursement with contracted PBMs and payers, CVS noted in a statement.
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter, according to a report released by Turquoise Health.
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced yesterday.